Invivyd, Inc. Files 8-K
Ticker: IVVD · Form: 8-K · Filed: Sep 4, 2024 · CIK: 1832038
| Field | Detail |
|---|---|
| Company | Invivyd, INC. (IVVD) |
| Form Type | 8-K |
| Filed Date | Sep 4, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
Invivyd filed a routine 8-K, no major news.
AI Summary
Invivyd, Inc. filed an 8-K on September 4, 2024, to report other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is incorporated in Delaware and has its principal executive offices in Waltham, MA. This filing does not appear to contain specific financial figures or material events beyond routine reporting.
Why It Matters
This 8-K filing indicates Invivyd, Inc. is making a regulatory submission to the SEC, which is standard practice for public companies to disclose material events or financial information.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and financial statements, with no specific material disclosures that would immediately impact risk.
Key Players & Entities
- Invivyd, Inc. (company) — Registrant
- Adagio Therapeutics, Inc. (company) — Former Name
- September 4, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Waltham, MA (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Invivyd, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of September 4, 2024.
When was Invivyd, Inc. formerly known as?
Invivyd, Inc. was formerly known as Adagio Therapeutics, Inc.
In which state is Invivyd, Inc. incorporated?
Invivyd, Inc. is incorporated in Delaware.
What is the address of Invivyd, Inc.'s principal executive offices?
The address of Invivyd, Inc.'s principal executive offices is 1601 Trapelo Road, Suite 178, Waltham, MA 02451.
What is the SEC file number for Invivyd, Inc.?
The SEC file number for Invivyd, Inc. is 001-40703.
Filing Stats: 442 words · 2 min read · ~1 pages · Grade level 10.8 · Accepted 2024-09-04 07:10:13
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share IVVD The Nasdaq Stock Mar
Filing Documents
- ivvd-20240904.htm (8-K) — 49KB
- ivvd-ex99_1.htm (EX-99.1) — 28KB
- img59752938_0.jpg (GRAPHIC) — 12KB
- 0000950170-24-103100.txt ( ) — 223KB
- ivvd-20240904.xsd (EX-101.SCH) — 31KB
- ivvd-20240904_htm.xml (XML) — 5KB
01
Item 8.01. Other Events. On September 4, 2024, Invivyd, Inc. issued a press release entitled "Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA." A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference in this Item 8.01.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated September 4, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INVIVYD, INC. Date: September 4, 2024 By: /s/ Jill Andersen Jill Andersen Chief Legal Officer and Corporate Secretary